---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-004017"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T01:30:25.636961+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Armata reports Q4 2022 loss of $10.3M; positive phage trial data, $30M financing closed

## Summary
- R&D expenses $9.6M in Q4 2022, up from $4.8M in Q4 2021, driven by clinical trial investment.
- Cash $14.9M at Dec 31, 2022; closed $30M convertible credit with Innoviva in Q4.
- Positive topline results from SWARM-P.a. Phase 1b/2a for AP-PA02 in CF patients; advancing to Phase 2b.
- First patient dosed in Phase 2 NCFB study for AP-PA02; AP-SA02 bacteremia study first cohort completed.
- Loss from operations $(10.3)M vs $(6.0)M in Q4 2021; grant revenue $1.1M.

## SEC filing metadata
- accession: 0001558370-23-004017
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000155837023004017/0001558370-23-004017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000155837023004017/armp-20230316x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-004017
- JSON: https://secwatch.observer/filing/0001558370-23-004017.json
- Plain text: https://secwatch.observer/filing/0001558370-23-004017.txt

## Key facts
- Earnings Releases
  Armata Pharmaceuticals, Inc. reported financial results for full fiscal year ended December 31, 2022.
  - Period: full fiscal year ended December 31, 2022
  - Result: reported results
  source text: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000155837023004017/0001558370-23-004017-index.htm
- Earnings Releases
  Armata Pharmaceuticals, Inc. reported three months ended December 31, 2022 results: revenue approximately $1.1 million.
  - Period: three months ended December 31, 2022
  - Revenue: approximately $1.1 million
  - Result: reported results
  source text: team is well-positioned for a successful 2023,” concluded Dr. Varnum. Fourth Quarter 2022 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.1 million for the three months ended December 31, 2022, which represents Medical Technology Enterprise Consortium (“MTEC”)’s share of the costs incurred for the Company’s AP-SA02 program
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000155837023004017/0001558370-23-004017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.